SVRA NASDAQ
Savara Inc.
1W: -7.1%
1M: -15.9%
3M: -15.6%
YTD: -16.3%
1Y: +53.8%
3Y: +137.2%
5Y: +206.5%
$5.08
+0.36 (+7.63%)
After Hours: $4.98 (-0.10, -1.87%)
Weekly Expected Move ±7.6%
$4
$5
$5
$5
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.0B
52W Range1.89-7.005
Volume1,134,451
Avg Volume1,554,744
Beta0.28
Dividend—
Analyst Ratings
Company Info
CEOMatthew Pauls
Employees59
SectorHealthcare
IndustryBiotechnology
IPO Date2017-04-28
Websitesavarapharma.com
Building III
Langhorne, TX 78746
US
Langhorne, TX 78746
US
512 614 1848
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Latest News
Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of “Moderate Buy” by Brokerages
FY2026 EPS Estimates for Savara Decreased by Lifesci Capital
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Brokerages
HC Wainwright Has Pessimistic View of Savara FY2026 Earnings
What is Lifesci Capital’s Estimate for Savara Q2 Earnings?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lowrance David L | M-Exempt | 24,850 | $3.35 | 2026-03-18 |
| Lowrance David L | M-Exempt | 12,500 | $4.45 | 2026-03-18 |
| Lowrance David L | F-InKind | 16,518 | $5.04 | 2026-03-18 |
| Lowrance David L | M-Exempt | 43,063 | $1.11 | 2026-03-18 |
| Lowrance David L | F-InKind | 11,037 | $5.04 | 2026-03-18 |